Archive for the ‘Anthrax’ Category
Using national surveillance data for 120,111 human anthrax cases recorded during 1955−2014, we analyzed the temporal, seasonal, geographic, and demographic distribution of this disease in China. After 1978, incidence decreased until 2013, when it reached a low of 0.014 cases/100,000 population. The case-fatality rate, cumulatively 3.6% during the study period, has also decreased since 1990. Cases occurred throughout the year, peaking in August. Geographic distribution decreased overall from west to east, but the cumulative number of affected counties increased during 2005−2014. The disease has shifted from industrial to agricultural workers; 86.7% of cases occurred in farmers and herdsmen. Most (97.7%) reported cases were the cutaneous form. Although progress has been made in reducing incidence, this study highlights areas that need improvement. Adequate laboratory diagnosis is lacking; only 7.6% of cases received laboratory confirmation. Geographic expansion of the disease indicates that livestock control programs will be essential in eradicating anthrax.
|Li Y, Yin W, Hugh-Jones M, Wang L, Mu D, Ren X, et al. Epidemiology of Human Anthrax in China, 1955−2014. Emerg Infect Dis. 2017;23(1):14-21. https://dx.doi.org/10.3201/eid2301.150947|
Anthrax postexposure prophylaxis (PEP) was recommended to 42 people after a laboratory incident & 3/4 didn’t finish taking it. How come?Wednesday, December 21st, 2016
Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events. Nolen Leisha D., Traxler Rita M., Kharod Grishma A., Kache Pallavi A., Katharios-Lanwermeyer Stefan, Hendricks Katherine A., Shadomy Sean V., Bower William A., Meaney-Delman Dana, and Walke Henry T.. Health Security. December 2016, 14(6): 419-423. doi:10.1089/hs.2016.0060.
“…..At least 31 (74%) individuals who initiated PEP did not complete either the recommended 60 days of antimicrobial therapy or the 3-dose vaccine regimen. Among the 29 that discontinued the antimicrobial component of PEP, most (38%) individuals discontinued PEP because of their low perceived risk of infection; 9 (31%) individuals discontinued prophylaxis due to PEP-related minor adverse events, and 10% cited both low risk and adverse events as their reason for discontinuation. Most minor adverse events reported were gastrointestinal complaints, and none required medical attention……”